within Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01A_AnteriorPituitaryLobeHormonesAndAnalogues.H01AC03_Mecasermin;

model Mecasermin
  extends Pharmacolibrary.Drugs.ATC.H.H01AC03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>H01AC03</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Mecasermin is a recombinant human insulin-like growth factor-1 (rhIGF-1) used to treat growth failure in children with severe primary IGF-1 deficiency or with growth hormone gene deletion who have developed neutralizing antibodies to growth hormone. It is approved for clinical use in certain pediatric patients with growth disorders.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are reported in children with severe primary IGF-1 deficiency receiving subcutaneous administration of mecasermin.</p><h4>References</h4><ol><li><p>Keating, GM (2008). Mecasermin. <i>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</i> 22(3) 177–188. DOI:<a href=\"https://doi.org/10.2165/00063030-200822030-00004\">10.2165/00063030-200822030-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18481900/\">https://pubmed.ncbi.nlm.nih.gov/18481900</a></p></li><li><p>Williams, RM, et al., &amp; Dunger, DB (2008). Mecasermin rinfabate: rhIGF-I/rhIGFBP-3 complex: iPLEX. <i>Expert opinion on drug metabolism &amp; toxicology</i> 4(3) 311–324. DOI:<a href=\"https://doi.org/10.1517/17425255.4.3.311\">10.1517/17425255.4.3.311</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18363546/\">https://pubmed.ncbi.nlm.nih.gov/18363546</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Mecasermin;
